Rare diseases
Investigational molecules
Locations
26 Rue D Ulm, 75005 Paris, France
Research activity is concentrated in breast cancer, with strong emphasis on triple-negative breast cancer (TNBC) across early-stage, high-risk, locally advanced, and metastatic settings. The portfolio also includes HER2-positive disease, ER-positive, HER2-negative metastatic disease, and molecularly defined subgroups such as GATA3-mutant and HER3-mutant breast cancer.
Interest extends to recurrence detection, biomarker-guided treatment selection, and post-treatment monitoring in advanced breast malignancies.
Institut Curie runs clinical trials in conditions such as Triple negative breast cancer, Retinoblastoma, Breast cancer metastatic, Breast cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
FranceFranceFranceFranceFranceFranceFranceFranceFranceFranceFranceFranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
